{"entity":{"id":"future-super","kind":"trial","name":"FUTURE-SUPER","aka":["FUTURE SUPER","NCT04395989"],"tldr":"FUTURE-SUPER tested a defined subtype-linked treatment strategy in advanced TNBC. The pooled phase 2 PFS comparison was positive; the current registry does not establish availability.","summary":"Single-centre, open-label phase 2 study at Fudan University Shanghai Cancer Center. Participants were women aged 18-70, ECOG 0-1, with untreated metastatic or recurrent TNBC. Five cohorts combined a Fudan subtype classification with genomic biomarkers. Within that strategy, 139 participants were randomised to matched additions to nab-paclitaxel (69) or nab-paclitaxel alone (70). This is a different classifier from Lehmann TNBCtype-4.\n\nThe primary comparison was investigator-assessed progression-free survival in the pooled intention-to-treat groups. At the 31 May 2023 cutoff, median follow-up was 22.5 months (interquartile range 15.2-29.0). It tested a package of classification, matching rules and regimens; it did not separately establish each component's effect.","status":"positive","asOf":"2026-11-09","links":[{"label":"ClinicalTrials.gov NCT04395989","url":"https://clinicaltrials.gov/study/NCT04395989"},{"label":"Fan et al., Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial (Lancet Oncol 2024)","url":"https://pubmed.ncbi.nlm.nih.gov/38211606/"}],"tags":["education-audit","subtyping-strategy"],"related":["paper-future-super-lancet-oncology-2024"],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["nab-paclitaxel","pyrotinib","everolimus","camrelizumab","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":["tnbc-molecular-subtyping"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-future-super-lancet-oncology-2024"],"journals":[],"dependsOn":[],"notes":["The four Fudan subtype labels generated five treatment cohorts after genomic splitting. Additions included pyrotinib for LAR with activating HER2 mutation; everolimus in specified PI3K/AKT-altered LAR/MES groups; camrelizumab plus famitinib in IM; and bevacizumab in BLIS/MES without those alterations. This does not equate those groups with TNBCtype-4 or pathology receptor labels.","The positive outcome label refers to the published pooled primary comparison. Registry recruitment status captured on 9 November 2026 is UNKNOWN, last known ACTIVE_NOT_RECRUITING; last posted update 22 December 2023. It is not an available-slot claim. Registry actual enrollment is 139 and no results module is posted.","The registry uses enrollment for its PFS clock and first dose for its secondary OS clock. Do not silently make those endpoints share a start or turn the PFS result into a demonstrated OS benefit."],"nct":"NCT04395989","phase":"2","design":"superiority","setting":"Single-centre first-line untreated metastatic/recurrent TNBC; Fudan subtype/genomic-marker cohorts, matched combinations plus nab-paclitaxel versus nab-paclitaxel alone","sponsor":"Fudan University","result":"At the 31 May 2023 analysis, median PFS was 11.3 versus 5.8 months, hazard ratio 0.44 (95 percent confidence interval 0.30-0.65). Treatment-related serious events occurred in 7/69 versus 0/70.","started":"2020-07-28","startedType":"actual","yearReported":2024,"enrolled":139,"enrolledBasis":"registry","outcomes":[{"endpoint":"Investigator-assessed progression-free survival, pooled intention-to-treat comparison","primary":true,"unit":"months","arms":[{"name":"Subtype/genomic-marker strategy plus nab-paclitaxel","n":69,"value":11.3,"note":"95 percent confidence interval 8.6-15.2"},{"name":"Nab-paclitaxel alone","n":70,"value":5.8,"note":"95 percent confidence interval 4.0-6.7"}],"hr":0.44,"ci":[0.3,0.65],"p":"<0.0001","source":"https://pubmed.ncbi.nlm.nih.gov/38211606/"}],"replication":"This single-centre phase 2 strategy result does not isolate a classifier or individual matched component; independent larger comparative validation and setting-specific comparators remain important."},"route":"/trials/future-super/","neighbours":{"paper":[{"id":"paper-future-super-lancet-oncology-2024","kind":"paper","name":"FUTURE-SUPER: first-line subtyping-based treatment in advanced TNBC","route":"/key-papers/paper-future-super-lancet-oncology-2024/"}],"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/"}],"term":[{"id":"tnbc-molecular-subtyping","kind":"term","name":"TNBC molecular subtyping","route":"/terms/tnbc-molecular-subtyping/"}],"person":[{"id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","route":"/people/jiang-yi-zhou/"},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/"}]}}